Highly commended

From Overlooked to Innovative: Turning an Underfunded Service into a Model of Innovation

by Bristol Myers Squibb with support from Lucid Group Communications

Summary of work

Historically, obstructive hypertrophic cardiomyopathy (HCM) care in the UK has been fragmented. Patients endured life-limiting symptoms like breathlessness and fainting. They travelled long distances for appointments and were limited to symptom-modifying treatments. Through the launch of mavacamten, we seized an opportunity to catalyse a transformational care pathway across inherited cardiac condition (ICC) services and beyond. Our initiative transcended mere treatment introduction: we fostered a coordinated, scalable, national approach. Over two years, we built deep relationships with ICC healthcare professionals (HCPs), catalysed shared-care models with non-specialist hospitals, and amplified access via outreach, hybrid learning, and peer-led “meeting in a box” toolkits. This empowered non-ICC cardiology teams to collaborate effectively in hubs and spokes, mitigating geographical disparities. Outcomes were striking: centres treating ICC patients expanded from 1 to 43 in two years; echocardiography service availability grew significantly; clinical confidence surged; and the proportion of unstable patients without the opportunity to change treatment more than halved. Most profoundly, patients have resumed their favourite hobbies (from playing the bagpipes, to 5-a-side) underscoring the human and systemic impact this transformational approach has brought to the NHS. This initiative exemplifies genuine care pathway revolution; far beyond prescribing, reshaping delivery and enabling equitable access to life-changing therapy.

Judges’ comments

BMS and Lucid’s entry had a clear approach, which was well thought through and evolved over time to reflect developing use of the product, learnings from use, and to incorporate different audiences/stakeholders. It had very impressive results across all objectives, including a shift from one centre treating HCM patients to 43 - a significant change in treatment patterns.